PBYI Share Price

Open 104.40 Change Price %
High 104.85 1 Day -0.30 -0.29
Low 102.65 1 Week -0.45 -0.43
Close 104.50 1 Month 21.80 26.36
Volume 359028 1 Year 36.42 53.50
52 Week High 109.85
52 Week Low 0.00
PBYI Important Levels
Resistance 2 106.54
Resistance 1 105.70
Pivot 104.00
Support 1 103.30
Support 2 102.46
NYSE USA Most Active Stocks
RAI 65.40 -2.23%
RAI 65.40 -2.23%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
SE 40.68 -0.78%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
BAC 25.02 -0.56%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
QUAD 22.58 14.21%
ANW 4.65 13.41%
MSB 23.45 12.20%
MSB 23.45 12.20%
FNP 35.24 12.02%
FNP 35.24 12.02%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Puma Biotechnology Inc (NYSE: PBYI)

PBYI Technical Analysis 5
As on 22nd Sep 2017 PBYI Share Price closed @ 104.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 56.45 & Strong Buy for SHORT-TERM with Stoploss of 91.55 we also expect STOCK to react on Following IMPORTANT LEVELS.
PBYI Target for September
1st Target up-side 105.45
2nd Target up-side 114.53
3rd Target up-side 123.6
1st Target down-side 79.55
2nd Target down-side 70.47
3rd Target down-side 61.4
PBYI Other Details
Segment EQ
Market Capital 620310592.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.pumabiotechnology.com
PBYI Address
PBYI
10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
Phone: 424-248-6500
Fax: 424-248-6501
PBYI Latest News
Interactive Technical Analysis Chart Puma Biotechnology Inc ( PBYI NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Puma Biotechnology Inc
PBYI Business Profile
Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products to enhance cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.